Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2026 and business updates.

“The resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a successful outcome,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “We continue to believe in tab-cel’s significant commercial potential in the U.S. In parallel, we are taking steps to control expenses with the goal of protecting and maximizing shareholder value while enhancing our strategic flexibility.”

Tabelecleucel (tab-cel® or EBVALLO™) for Post-Transplant Lymphoproliferative Disease (PTLD)

As previously communicated, the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for tabelecleucel, with a proposed indication as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.

The BLA has a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2027.

If tabelecleucel is approved by the FDA, Atara would be eligible to receive a $31 million milestone payment pursuant to Atara’s commercialization agreement with Pierre Fabre Laboratories. Atara would also be eligible to receive significant double-digit tiered royalties as a percentage of net sales, as well as milestones related to commercial sales of EBVALLO.

Third Quarter 2026 Financial Results:

  • Cash, cash equivalents and short-term investments as of September 30, 2026, totaled $9.9 million, as compared to $9.9 million as of June 30, 2026.

  • Net cash used in operating activities was $0.9 million for the third quarter 2026, as compared to $9.8 million in the same period in 2025.

  • Total revenues were $1.2 million for the third quarter 2026, as compared to $3.5 million for the same period in 2025. Total revenues decreased by $2.3 million year-over-year, primarily due to the one-time sale of clinical inventory in the prior year.

  • Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $0.5 million for the third quarter 2026, as compared to $1.3 million for the same period in 2025.

  • Research and development expenses were $1.1 million for the third quarter 2026, as compared to $2.9 million for the same period in 2025.

  • Research and development expenses include $0.1 million of non-cash stock-based compensation expenses for the third quarter 2026, as compared to $0.3 million for the same period in 2025.

  • General and administrative expenses were $2.8 million for the third quarter 2026, as compared to $4.0 million for the same period in 2025.

  • General and administrative expenses include $0.4 million of non-cash stock-based compensation expenses for the third quarter 2026, as compared to $0.9 million for the same period in 2025.

  • Atara reported a net loss of $2.2 million, or ($0.15) basic and diluted loss per share, for the third quarter 2026, as compared to net loss of $4.3 million, or ($0.32) basic and diluted loss per share, for the same period in 2025.

2026 Outlook and Cash Runway:

  • Operating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025 and the first half of 2026.

  • Atara expects its cash, cash equivalents, and short-term investments as of September 30, 2026, combined with operating efficiencies achieved in 2025 and the first half of 2026, will be sufficient to fund planned operations into mid-2027.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.

Forward-Looking Statements

This press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the FDA’s review of the resubmitted tab-cel BLA and the PDUFA target action date, the potential characteristics and benefits of tab-cel, and the results of, and prospects for bringing tab-cel to U.S. patients with EBV+ PTLD, the global partnership with Pierre Fabre Medicament involving tab-cel, and the potential financial benefits to Atara as a result of the global partnership with Pierre Fabre Medicament, including the receipt, timing and amount of any payments to be received by Atara thereunder; and (2) Atara’s cash runway, receipt of potential milestone payments, and estimated reduction in operating expenses, including Atara’s ability to fund its planned operations into mid-2027. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA’s review of tab-cel, including the risk that the resubmitted tab-cel BLA may not address the deficiencies identified in the Complete Response Letter received on January 9, 2026 or other issues that may be raised by the FDA on review; the fact that PFP, and not Atara, holds the tab-cel BLA and controls the content and strategy of the BLA and related FDA interactions, and Atara’s ability to influence the review process is limited; Atara’s ability to continue as a going concern and access capital, and the sufficiency of Atara’s cash resources and access to additional capital on favorable terms or at all; and other risks and uncertainties affecting Atara, including those discussed in Atara’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Atara’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

ATARA BIOTHERAPEUTICS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except per share amounts)

 

 

 

 

 

 

 

 

September 30,

 

December 31,

 

 

2026

 

2025

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

4,055

 

 

$

8,482

 

Short-term investments

 

 

5,862

 

 

 

—

 

Accounts receivable

 

 

691

 

 

 

1,253

 

Other current assets

 

 

705

 

 

 

2,477

 

Total current assets

 

 

11,313

 

 

 

12,212

 

Property and equipment, net

 

 

38

 

 

 

73

 

Operating lease assets

 

 

6,494

 

 

 

7,064

 

Other assets

 

 

762

 

 

 

886

 

Total assets

 

$

18,607

 

 

$

20,235

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity (deficit)

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

762

 

 

$

127

 

Accrued compensation

 

 

471

 

 

 

1,271

 

Accrued research and development expenses

 

 

24

 

 

 

82

 

Deferred revenue

 

 

513

 

 

 

716

 

Liability related to the sale of future revenues – current portion

 

 

1,105

 

 

 

9,750

 

Other current liabilities

 

 

3,693

 

 

 

2,976

 

Total current liabilities

 

 

6,568

 

 

 

14,922

 

Operating lease liabilities – long-term

 

 

8,482

 

 

 

9,347

 

Liability related to the sale of future revenues – long-term

 

 

39,560

 

 

 

32,673

 

Other long-term liabilities

 

 

1,899

 

 

 

1,795

 

Total liabilities

 

 

56,509

 

 

 

58,737

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

Common stock—$0.0001 par value, 500,000 shares authorized as of September 30, 2026 and December 31, 2025; 10,188 and 7,324 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

1,995,171

 

 

 

1,983,361

 

Accumulated other comprehensive income (loss)

 

 

(1

)

 

 

1

 

Accumulated deficit

 

 

(2,033,073

)

 

 

(2,021,865

)

Total stockholders’ equity (deficit)

 

 

(37,902

)

 

 

(38,502

)

Total liabilities and stockholders’ equity (deficit)

 

$

18,607

 

 

$

20,235

 

ATARA BIOTHERAPEUTICS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(In thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

Commercialization revenue

 

$

1,224

 

 

$

3,453

 

 

$

2,370

 

 

$

119,177

 

Costs and operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of commercialization revenue

 

 

265

 

 

 

115

 

 

 

580

 

 

 

21,108

 

Research and development expenses

 

 

1,099

 

 

 

2,925

 

 

 

2,608

 

 

 

37,668

 

General and administrative expenses

 

 

2,830

 

 

 

3,987

 

 

 

10,241

 

 

 

21,976

 

Total costs and operating expenses

 

 

4,194

 

 

 

7,027

 

 

 

13,429

 

 

 

80,752

 

Income (loss) from operations

 

 

(2,970

)

 

 

(3,574

)

 

 

(11,059

)

 

 

38,425

 

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

68

 

 

 

204

 

 

 

199

 

 

 

583

 

Interest income (expense) on sale of future revenues

 

 

682

 

 

 

(906

)

 

 

(333

)

 

 

(2,745

)

Other income (expense), net

 

 

(9

)

 

 

1

 

 

 

(14

)

 

 

(138

)

Total other income (expense), net

 

 

741

 

 

 

(701

)

 

 

(148

)

 

 

(2,300

)

Income (loss) before provision for (benefit from) income taxes

 

 

(2,229

)

 

 

(4,275

)

 

 

(11,207

)

 

 

36,125

 

Provision for (benefit from) income taxes

 

 

—

 

 

 

28

 

 

 

1

 

 

 

31

 

Net income (loss)

 

$

(2,229

)

 

$

(4,303

)

 

$

(11,208

)

 

$

36,094

 

Other comprehensive gain (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities

 

 

1

 

 

 

2

 

 

 

(2

)

 

 

(6

)

Comprehensive income (loss)

 

$

(2,228

)

 

$

(4,301

)

 

$

(11,210

)

 

$

36,088

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic (loss) earnings per common share

 

$

(0.15

)

 

$

(0.32

)

 

$

(0.76

)

 

$

2.96

 

Diluted (loss) earnings per common share

 

$

(0.15

)

 

$

(0.32

)

 

$

(0.76

)

 

$

2.93

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted weighted-average shares outstanding

 

 

15,326

 

 

 

13,564

 

 

 

14,818

 

 

 

12,185

 

Diluted weighted-average shares outstanding

 

 

15,326

 

 

 

13,564

 

 

 

14,818

 

 

 

12,319

 

 

Media gallery

About The Author
Business Wire